Endocrine Abstracts

Introduction: Hypercalcemia due to parathyroid-hormone-related-peptide (PTHrP) is rare in neuroendocrine tumours.A 63-year-old lady initially presented to ENT surgeons with symptoms of reflux, dysphagia, and weight loss. Past medical history included hysterectomy eight years previously for uterine prolapse. There was no family history of note. Investigations revealed corrected calcium was elevated at 2.94 (2.1–2.5) mmol/l. ALP: 184 (30–135) U/l...

This study was designed to evaluate whether weight change in type 2 diabetes leads to deteriorating glycaemic control necessitating treatment escalation, or whether deteriorating glycaemic control results in medication change and possible weight gain.We studied 702 type 2 diabetic subjects with a follow-up of 56 plus/minus 2 months (mean plus/minus S.E.) treated on diet, metformin or sulphonylurea, alone or in combination. Patients who remained on diet alone (40 plus/minus...

The Diabetes Control and Complications Study, United States, and the United Kingdom Prospective Diabetes Study both reported increasing weight gain in all groups of patients with diabetes. The present study was designed to examine retrospectively if this was the experience in a clinic with an emphasis on weight loss as a central component of the treatment offered, facilitated by frequent clinic visits, the attendance of a dietitian at all clinics, a relatively low rate of insu...

Guidelines for the use of Growth Hormone (GH) replacement in adults with GH deficiency (GHD) were published by the National Institute for Clinical Excellence (NICE) in 2003. We undertook an audit to ensure that patients attending our adult endocrinology clinic were being prescribed GH in accordance with NICE guidelines.Patients commenced on GH replacement between June 2004 and June 2005 were included in the audit. Data was collected from medical notes, a...

In a double-blind study, 106 patients (44 males, 62 females, age 20-64 years) with Addison's disease, were randomised to receive either 50mg of micronised DHEA or placebo orally daily for 12 months. Psychological and biochemical parameters were measured at baseline, 3 to 6 month intervals and post-washout; bone mineral density (BMD) and body composition were assessed by DEXA at baseline and 12 months.DHEAS levels rose significantly and were maintained th...

BACKGROUND: Primary hyperparathyroidism (HPT) is increasingly diagnosed, particularly in an older population. Recent studies indicate improvement in bone mineral density (BMD) and psychological wellbeing even following treatment of apparent asymptomatic disease, supporting a lower threshold for surgical intervention. With disease being due to a solitary adenoma in most (83%) cases, we have utilised preoperative imaging together with intra-operative parathyroid hormone (IOPTH) ...